Publication Introduction Lykke Sylow

On 14.08.2025, Prof. Dr. Lykke Sylow from the University of Copenhagen presented the latest findings on "Activin receptor type IIA/B blockade increases muscle mass and strength, but compromises glycemic control in mice," which focuses on the role of Activin Receptors IIA/B in the regulation of muscle mass and metabolic processes. The studies show that blocking these receptors significantly increases muscle strength and mass in lean and obese mice. However, an impairment in glycemic control was also observed—a phenomenon not seen in humans in this form. Notably, the combination therapy with Semaglutide and Bimagrumab, which in preclinical studies led to a significant reduction in body fat while preserving muscle mass, is worth highlighting. The results raise important questions about the transferability of animal experimental data to humans and offer new insights for developing therapies against sarcopenia and metabolic diseases.

https://www.biorxiv.org/content/10.1101/2025.06.11.659035v1.full

HyperMet research examines the impact of muscle growth (hypertrophy) and muscle loss (atrophy) on metabolism. Increased muscle mass reduces the risk of obesity, diabetes, osteoporosis, and potentially cancer. We are exploring the underlying metabolic processes to develop new strategies for prevention and everyday life.